Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their lives to the fullest.

Who We Are

Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease transforming therapeutics for CNS-mediated conditions

Top wave

Our Pipeline

Three mid-clinical-stage therapeutics designed to improve the lives of patients with the following CNS-mediated diseases: Persistent Seizures in Tuberous Sclerosis Complex, Severe Pain in Trigeminal Neuralgia, Involuntary Tics associated with Tourette Syndrome, Childhood Onset Fluency Disorder, and an additional, undisclosed indication.

Educational Resources

We’re committed to sharing important disease-state information that informs patients and helps them foster connections with others living with similar conditions.

Partnerships and Investors

Strategic collaborations and investments enable us to develop world-class treatments for people with rare and often-overlooked conditions of the central nervous system.